Abstract
BackgroundThe first-line treatment for GBS is plasma exchange or intravenous immunoglobulin. In contrast, corticosteroids are not recommended for treating GBS. However, COVID-19–related Guillain–Barré syndrome occurs via mechanisms different from other infectious diseases. Case reportA 63-year-old woman experienced back pain following COVID-19, progressing to numbness/weakness of the extremities, left peripheral facial nerve palsy, and abnormal sensation/allodynia in the face and extremities. Compound muscle action potentials showed severe temporal dispersion. Intravenous immunoglobulin administration slightly improved the lower limb muscle weakness and facial nerve palsy but was ineffective for the pain in the chest and back and numbness of the extremities. Three courses of intravenous methylprednisolone (IVMP) enabled the patient to walk unassisted. ConclusionsThis case is the first to demonstrate IVMP's effectiveness against COVID-19–related Guillain–Barré syndrome. Further studies are required to establish treatments for COVID-19–related Guillain–Barré syndrome.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
